What changed · written from our data
As of Nov 2, 2026Aspen Neuroscience closed at $13.04 on Nov 2, down 12.42%, within 0.0% of its lowest close since Oct 30.
NASDAQ · ASPE
Aspen Neuroscience, Inc. Common Stock (ASPE)
$13.04−12.42%
Close Nov 2, 2026 · split-adjustedNov 2, 2026$13.04▼ 12.42% in range
Oct 30, 2026Low $13.04 · High $14.89Nov 2, 2026
Market cap$379.2M29.1M shares
Revenue · quarter——
Diluted EPS——
P/E · TTM—
Net margin—
Dividend yieldNone
Range since Oct 3013.04 – 14.89−12.4% from high
Volume596.6K
Volatility · 60d—Annualised
Short % of float—
Net cash—
Next earnings—Not scheduled
Split-adjusted performance
1W —1M —3M —6M —YTD —1Y —3Y —5Y —Earnings reactions
History →No reported quarters with price history yet.
Rank within industry
Not enough peers to rank
6-month momentum—
Revenue growth—
Net margin—
Value (low P/E)—
Size—
Short interest
Details →No short interest reported.
News about Aspen Neuroscience
All news →No recent articles focused on Aspen Neuroscience.
Quick answers
- What does Aspen Neuroscience do?
- Aspen Neuroscience Inc is a clinical-stage, regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to initially address neurodegenerative diseases with high unmet medical need. The company's flagship program, sasineprocel, is an investigational autologous iPSC-based therapy for Parkinson's disease designed to replace a patient's lost dopamine neurons with dopaminergic neuron precursor cells.
- What is ASPE's market cap?
- $379.18M, based on the Nov 2 close of $13.04.
About Aspen Neuroscience
Aspen Neuroscience Inc is a clinical-stage, regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to initially address neurodegenerative diseases with high unmet medical need. The company's flagship program, sasineprocel, is an investigational autologous iPSC-based therapy for Parkinson's disease designed to replace a patient's lost dopamine neurons with dopaminergic neuron precursor cells.
Listed Oct 30, 2026aspenneuroscience.com
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology